Press Releases Filter by year Select Year 2021 2020 2019 2018 January 11, 2021 Starton Therapeutics Selects Formulation for Continuous Subcutaneous Lenalidomide Delivery System for CLL Treatment September 14, 2020 Keith Darragh Joins Starton Therapeutics as Chief Financial Officer September 9, 2020 Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors August 25, 2020 Cidnee Vaykovich Named Starton Therapeutics Chief Operating Officer July 28, 2020 Starton Therapeutics to Present at the LifeSci Partners Summer Symposium April 30, 2020 Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents December 27, 2019 Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide December 26, 2019 Starton Therapeutics: Announcing Name Change for ChemioCare Inc December 18, 2019 ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System August 29, 2019 ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein April 29, 2019 ChemioCare Announces Appointment of Roy F. Waldron to Its Board of Directors April 23, 2019 ChemioCare Announces Initiation of PETT Based (Permeation Enhanced Transdermal Technology) Lenalidomide Program February 6, 2019 ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch January 7, 2019 ChemioCare Strengthens Executive Management Team January 4, 2019 ChemioCare Initiates Development Program in Pediatric CINV October 18, 2018 ChemioCare Expands Proprietary Transdermal Platform July 30, 2018 ChemioCare Announces Addition of Three Experienced Team Members May 1, 2018 ChemioCare Announces Addition of Chief Medical Advisor and Director March 6, 2018 ChemioCare Formed to Transform Chemo-Induced Emesis Outcomes Through Patch Technology
